These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7104169)

  • 21. Intravenous labetalol in hypertensive patients treated with beta-adrenoreceptor-blocking drugs.
    Pearson RM; Havard CW
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):795-8. PubMed ID: 10953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism of labetalol by animals and man.
    Martin LE; Hopkins R; Bland R
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, beta-adrenoceptor blockade and anti-hypertensive action of labetalol during chronic oral treatment.
    Sanders GL; Davies DM; Rawlins MD
    Br J Clin Pharmacol; 1980 Aug; 10(2):121-6. PubMed ID: 6252915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition.
    Lalonde RL; O'Rear TL; Wainer IW; Drda KD; Herring VL; Bottorff MB
    Clin Pharmacol Ther; 1990 Nov; 48(5):509-19. PubMed ID: 2225711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of labetalol and propranolol on histamine-induced bronchoconstriction in normal subjects.
    Maconochie JG; Woodings EP; Richards DA
    Br J Clin Pharmacol; 1977 Apr; 4(2):157-62. PubMed ID: 861131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol.
    Trust PM; Rosei EA; Brown JJ; Fraser R; Lever AF; Morton JJ; Robertson JI
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):799-803. PubMed ID: 791333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of dilevalol in normotensive and hypertensive volunteers.
    Kramer WG; Perentesis G; Affrime MB; Patrick JE
    Am J Cardiol; 1989 Jun; 63(19):7I-11I. PubMed ID: 2729127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients.
    Carvalho TM; Cavalli Rde C; Cunha SP; de Baraldi CO; Marques MP; Antunes NJ; Godoy AL; Lanchote VL
    Eur J Clin Pharmacol; 2011 Jan; 67(1):55-61. PubMed ID: 20848091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Relative biological availability of labetalol after the administration of the Trandate (Allen & Hanburys) and Coreton (VULM) preparations].
    Kusala S; Janků I; Elis J; Fedelesová V; Ostrovská V; Stará D; Svobodová X; Kamenská R
    Cesk Fysiol; 1987; 36(1):78-85. PubMed ID: 3568169
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antihypertensive effects of labetalol administered parenterally and orally].
    Nicolaescu V; Serban-Pârâu G; Ionescu P; Nuţă M
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1984; 36(5):405-12. PubMed ID: 6151227
    [No Abstract]   [Full Text] [Related]  

  • 31. Affinity of labetalol for ocular melanin.
    Poynter D; Martin LE; Harrison C; Cook J
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):711-20. PubMed ID: 990153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prazosin, pharmacokinetics and concentration effect.
    Bateman DN; Hobbs DC; Twomey TM; Stevens EA; Rawlins MD
    Eur J Clin Pharmacol; 1979 Sep; 16(3):177-81. PubMed ID: 499317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular effects of labetalol during halothane anaesthesia.
    Scott DB; Buckley FP; Drummond GB; Littlewoods DG; Macrae WR
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):817-21. PubMed ID: 990159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The determination of labetalol in plasma by high-performance liquid chromatography using fluorescence detection.
    Meredith PA; McSharry D; Elliott HL; Reid JL
    J Pharmacol Methods; 1981 Dec; 6(4):309-14. PubMed ID: 7334812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological effects of labetalol in man.
    Richards DA
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):721-3. PubMed ID: 10949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of dixyrazine: low bioavailability, improved by food intake.
    Liedholm H; Lidén A; Kroon L; Melander A; Wåhlin-Boll E
    Drug Nutr Interact; 1985; 3(2):87-92. PubMed ID: 3987521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report.
    Louis WJ; McNeil JJ; Workman BS; Drummer OH; Conway EL
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S89-93. PubMed ID: 2454376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imipramine disposition in users of oral contraceptive steroids.
    Abernethy DR; Greenblatt DJ; Shader RI
    Clin Pharmacol Ther; 1984 Jun; 35(6):792-7. PubMed ID: 6734030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Labetalol in inadequately controlled hypertensive patients. A twice-daily oral regimen.
    Douglas-Jones AP
    Practitioner; 1980 Aug; 224(1346):841-4. PubMed ID: 7433403
    [No Abstract]   [Full Text] [Related]  

  • 40. Yohimbine bioavailability in humans.
    Guthrie SK; Hariharan M; Grunhaus LJ
    Eur J Clin Pharmacol; 1990; 39(4):409-11. PubMed ID: 2076728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.